On a consensus basis, brokerages on the Street have a mean target price of $45.055 for Oracle Corporation (NYSE:ORCL). This number is based on the mean estimate from the 18 research firms that recently issued reports on the company.
As many as 23 brokerage firms have rated Oracle Corporation (NYSE:ORCL) at 1.93. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
Oracle Corporation (NYSE:ORCL) has shown a rise of 27.5% or 7,537,790 shares in the short positions. The bets have increased to 34,913,013 shares on September 15,2015 from 27,375,223 shares on August 31,2015.
Oracle Corporation (NYSE:ORCL) traded with a cut of -0.61 points or -1.69% at $35.44 per share. As per the last available information, the stock aggregated $117.12 million in upticks and $82.49 million in downticks, keeping the net money flow capped at ...
Oracle Health Sciences, part of technology firm Oracle (ORCL), said LSK Global Pharma Services of South Korea adopted its cloud-based InForm to improve clinical development processes, data capture and to speed up trial timelines.
Oracle Corporation (NYSE:ORCL) has lost 0.91% during the past week and dropped 3.76% in the last 4 weeks. The shares have outperformed the S&P 500 by 0.46% in the past week but underperformed the index by 0.9% in the last 4 weeks.
Oracle Corporation (NYSE:ORCL) dropped slightly amid mild profit booking and the last known price was $35.94 per share. The price decreased by -0.12 points or -0.33% which made the investors to buy on weakness.